Adds background in paragraphs 2,3 and FDA comment in paragraph 4
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for a regulatory action on bluebird bio's BLUE.O gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional reports of blood cancers from its use.
Skysona was approved by the FDA in 2022 for the treatment of cerebral adrenoleukodystrophy.
The therapy's prescribing information included a warning for blood cancers, including leukemia and myelodysplastic syndromes, which are a group of cancers that occur when the bone marrow produces immature blood cells instead of healthy ones.
The FDA said considering the risk of such cancers, patients should consider alternative therapies.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.